Expert insights. Personalized for you.
29 percent of Americans said they were unlikely to get vaccinated — up from 24 percent three months earlier. Most workers do not want their own employer to require vaccination, including the vast majority of unvaccinated workers (92%). The post Is it time for vaccination mandates? MORE
The government has the latitude to protect citizens from deadly conditions, especially when the science supporting vaccination is so clear” We, as a nation, can not allow ignorance and stupidity to endanger us all. were for people who skipped out on getting vaccinated. MORE
Positive results from Clover's Phase 3 study could mean another coronavirus vaccine option for the many countries still grappling with short supplies MORE
Four months after vaccination, no 12- to 15-year-olds in the companies' clinical trial developed COVID-19, compared to 30 who received a placebo MORE
Several companies, including Pfizer and Moderna, are already at work adapting their coronavirus shots to the newly identified variant, which experts worry could more readily evade vaccine protection MORE
Scientists at Stanford University and the University of North Carolina at Chapel Hill have created a 3D-printed vaccine patch that provides greater protection than a typical vaccine shot. Social & Behavioral Science offers patch printed shot vaccination vaccine MORE
SUMMARY : Vaccine mandates are only going to get us so far when it comes to COVID immunity. The reasons for people refusing vaccines are both safety and side effect concerns, although politics plays a big part as well. As I See It COVID Vaccine MORE
New data, meanwhile, help affirm the benefit of a third dose of Moderna's current vaccine The study will test a version of the biotech's COVID-19 shot that's tailored to the infectious variant. MORE
The government-funded trial will evaluate the effects of mixing vaccines and varying timing between shots MORE
Drones have emerged as a speedy logistics option for time- and temperature-sensitive vaccine doses, potentially helping boost the availability of shots in rural areas MORE
Moderna is facing criticism for refusing to share its COVID-19 vaccine formula amid global vaccine shortages and continuing COVID-19 vaccine inequities. However, on Tuesday, Moderna told The Associated Press that it has “no plans to share the recipe for its COVID-19 vaccine.” MORE
The first public vaccinations with AstraZeneca and Oxford’s shot will begin early in the New Year. But it’s still unclear how effective the vaccine is, or the best way to use it MORE
The company has previously said it could make up to three billion vaccine doses in 2022, depending on how booster shots are authorized MORE
SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others. MORE
SUMMARY: Johnson & Johnson and AstraZeneca publicly committed to not profiting off their products during the pandemic; Pfizer and Moderna made no such pledge and are already planning ways to make more money from their Covid vaccines. The post Profiteering off a Covid vaccine. MORE
SUMMARY: Even though the Delta variant of COVID is highly contagious, people are still choosing not to get vaccinated. Concerns about safety, fear of unknown side effects, and misinformation about COVID-19 are some reasons why people may not accept the vaccine. MORE
You need to ask yourself why in the hell Pfizer’s CEO would say that their vaccine is 90% effective when there is a lot more testing and review of data needed. However, there’s still a long way to go before researchers can be certain that this vaccine is indeed as effective as promised. MORE
Highly anticipated results from a Phase 3 study testing the biotech company's shot showed it to be strongly protective and safe, a potential boon for the world's vaccination efforts MORE
These differences also explain why vaccines are necessary for both the flu and COVID-19. Read more Flu Vaccine vs. COVID-19 Vaccine. The post Flu Vaccine vs. COVID-19 Vaccine appeared first on MyLocalStudy.com. MORE
LA JOLLA, CA—Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2. Biology cells current fight Omicron teach Vaccines MORE
Despite low absolute risk, BNT162b2 COVID-19 vaccine associated with increased risk of carditis Markedly increased risk in adolescents after 2nd dose may warrant refined vaccination strategies Abstract: [link] URL goes live when the embargo lifts A case-control study found that despite low absolute risk, there is an increased relative risk of carditis associated with […]. Latest News BNT162b2 carditis COVID19 Increased risk vaccine MORE
The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday MORE
SUMMARY: The numbers game for COVOD-19 vaccine makers has started but what most of the public, and the media, don’t understand is that the preliminary numbers don’t mean a damn thing until they are peer-reviewed. As I See It COVID Vaccine MORE
A deal to fill vials of Pfizer and BioNTech's vaccine could be the first of several Novartis signs to help others make COVID-19 treatments MORE
A needle-free COVID-19 vaccination could be possible, with University of Queensland scientists successfully protecting mice from the virus by administering a US-developed vaccine candidate with a ‘patch’. Medicine & Health COVID19 Needlefree promise shows vaccine MORE
The sum is $11 billion higher than Pfizer had estimated in February and, if realized, would make the vaccine the highest grossing pharmaceutical product by revenue in a single year MORE
Philip Dormitzer, who helped Pfizer develop shots for COVID-19, RSV and influenza, will become the British pharma's head of vaccine R&D next month MORE
The FDA wants to better understand the risk of vaccine-associated myocarditis in 12- to 17-year-olds based on real-world use overseas, which will set back Moderna’s authorization plans in the U.S. MORE
The agency's emergency clearance makes J&J's vaccine the third available in the U.S., adding much-needed reinforcements at a critical time MORE
The emergency clearance greatly expands the pool of people who can be vaccinated in the U.S. just as some states are beginning to report waning demand MORE
Data from a small Phase 1 trial showed the biotech's vaccine spurred immune responses to four common strains, although they didn't appear significantly greater than an already available shot from Sanofi MORE
The pharma company, already partnered with BioNTech on vaccines for COVID-19 and influenza, will pay $225 million upfront to further expand its work with the German biotech MORE
Outside experts are reviewing Pfizer's application for emergency authorization of its vaccine in 5- to 11-year-olds. Follow their discussion with BioPharma Dive reporters live MORE
Days after the FDA strengthened safety warnings for the company's shot, a CDC panel recommended Pfizer's and Moderna's vaccines be "preferred" over J&J's MORE
The long-awaited decision could strengthen the case for vaccine mandates as public health officials seek to boost rates of immunization amid a wave of COVID-19 cases MORE
One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses MORE
(Mckinsey) Much of the prevailing market research on COVID-19 vaccination frames sentiment as “likely,” “unlikely,” or “neutral.” Their research has found that consumers’ attitudes towards receiving a COVID-19 vaccine fall into three primary segments. in the news COVID Vaccine MORE
Having proved mRNA's might in COVID-19, the biotech company aims to develop similar vaccines for other respiratory illnesses caused by influenza, RSV and metapneumovirus MORE
The vaccine, which Medicago plans to soon submit to Canadian regulators, would be the first of its type, though supply appears likely to be limited MORE
Agency scientists noted the shot's strong protection against severe COVID-19, even for the virus variant first detected in South Africa and known to weaken vaccine potency MORE
The government has latitude to protect citizens from deadly conditions, especially when the science supporting vaccination is so clear” With respect to children, parents do not have carte blanche. The post The Constitution and vaccinations. in the news Vaccinations & the law MORE
Chemistry AND Physics engineering nextgen VaccinesMost researchers hope they will be the one to discover the next big breakthrough advance for society, like finding a cure for cancer or climate change. MORE
Vaccination Related Topics World of DTC Marketing
AUGUST 26, 2021
The government has latitude to protect citizens from deadly conditions, especially when the science supporting vaccination is so clear” With respect to children, parents do not have carte blanche. The post The Constitution and vaccinations. in the news Vaccinations & the law
World of DTC Marketing
JULY 20, 2021
29 percent of Americans said they were unlikely to get vaccinated — up from 24 percent three months earlier. Most workers do not want their own employer to require vaccination, including the vast majority of unvaccinated workers (92%). The post Is it time for vaccination mandates?
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
NOVEMBER 30, 2021
Philip Dormitzer, who helped Pfizer develop shots for COVID-19, RSV and influenza, will become the British pharma's head of vaccine R&D next month
Bio Pharma Dive
JANUARY 5, 2022
The pharma company, already partnered with BioNTech on vaccines for COVID-19 and influenza, will pay $225 million upfront to further expand its work with the German biotech
Speaker: Nimesh Patel, Gregory Demitrack, and Sarah Barnes Humphrey
Register for our upcoming webinar to better understand the state of the pharmaceutical supply chain. FourKites partnered with Accenture to survey supply chain executives working in pharmaceuticals, biotech, cell and gene therapy, medtech, and other related industries.
World of DTC Marketing
NOVEMBER 10, 2020
You need to ask yourself why in the hell Pfizer’s CEO would say that their vaccine is 90% effective when there is a lot more testing and review of data needed. However, there’s still a long way to go before researchers can be certain that this vaccine is indeed as effective as promised.
World of DTC Marketing
SEPTEMBER 10, 2021
The government has the latitude to protect citizens from deadly conditions, especially when the science supporting vaccination is so clear” We, as a nation, can not allow ignorance and stupidity to endanger us all. were for people who skipped out on getting vaccinated.
World of DTC Marketing
MARCH 25, 2021
SUMMARY: Johnson & Johnson and AstraZeneca publicly committed to not profiting off their products during the pandemic; Pfizer and Moderna made no such pledge and are already planning ways to make more money from their Covid vaccines. The post Profiteering off a Covid vaccine.
Bio Pharma Dive
DECEMBER 16, 2021
Days after the FDA strengthened safety warnings for the company's shot, a CDC panel recommended Pfizer's and Moderna's vaccines be "preferred" over J&J's
Bio Pharma Dive
NOVEMBER 29, 2021
Several companies, including Pfizer and Moderna, are already at work adapting their coronavirus shots to the newly identified variant, which experts worry could more readily evade vaccine protection
World of DTC Marketing
NOVEMBER 16, 2020
SUMMARY: The numbers game for COVOD-19 vaccine makers has started but what most of the public, and the media, don’t understand is that the preliminary numbers don’t mean a damn thing until they are peer-reviewed. As I See It COVID Vaccine
Advertiser: Aggregage
The federal government is developing a rule requiring employers with more than 100 employees ensure their workers are vaccinated or produce a negative COVID test weekly before entering the workplace. So, what can your organization do to prepare? Get Paycor’s COVID Vaccination Policy Template to help communicate important details to your employees.
Scienmag
SEPTEMBER 24, 2021
Scientists at Stanford University and the University of North Carolina at Chapel Hill have created a 3D-printed vaccine patch that provides greater protection than a typical vaccine shot. Social & Behavioral Science offers patch printed shot vaccination vaccine
|
Bio Pharma Dive
OCTOBER 26, 2021
Outside experts are reviewing Pfizer's application for emergency authorization of its vaccine in 5- to 11-year-olds. Follow their discussion with BioPharma Dive reporters live
World of DTC Marketing
JANUARY 8, 2021
SUMMARY: Pfizer and Moderna will sell $28 billion of Covid-19 vaccines this year. Pharma companies will make an estimated $40 billion on the global COVID-19 vaccine market this year, which will be split between Johnson & Johnson, AstraZeneca, Novavax, and others.
Bio Pharma Dive
SEPTEMBER 22, 2021
Positive results from Clover's Phase 3 study could mean another coronavirus vaccine option for the many countries still grappling with short supplies
World of DTC Marketing
JULY 19, 2021
SUMMARY: Even though the Delta variant of COVID is highly contagious, people are still choosing not to get vaccinated. Concerns about safety, fear of unknown side effects, and misinformation about COVID-19 are some reasons why people may not accept the vaccine.
Bio Pharma Dive
DECEMBER 10, 2021
Data from a small Phase 1 trial showed the biotech's vaccine spurred immune responses to four common strains, although they didn't appear significantly greater than an already available shot from Sanofi
World of DTC Marketing
DECEMBER 11, 2020
(Mckinsey) Much of the prevailing market research on COVID-19 vaccination frames sentiment as “likely,” “unlikely,” or “neutral.” Their research has found that consumers’ attitudes towards receiving a COVID-19 vaccine fall into three primary segments. in the news COVID Vaccine
Bio Pharma Dive
AUGUST 23, 2021
The long-awaited decision could strengthen the case for vaccine mandates as public health officials seek to boost rates of immunization amid a wave of COVID-19 cases
World of DTC Marketing
SEPTEMBER 27, 2021
SUMMARY : Vaccine mandates are only going to get us so far when it comes to COVID immunity. The reasons for people refusing vaccines are both safety and side effect concerns, although politics plays a big part as well. As I See It COVID Vaccine
Bio Pharma Dive
AUGUST 25, 2021
Drones have emerged as a speedy logistics option for time- and temperature-sensitive vaccine doses, potentially helping boost the availability of shots in rural areas
Bio Pharma Dive
JANUARY 26, 2022
New data, meanwhile, help affirm the benefit of a third dose of Moderna's current vaccine The study will test a version of the biotech's COVID-19 shot that's tailored to the infectious variant.
Scienmag
JANUARY 24, 2022
LA JOLLA, CA—Scientists at La Jolla Institute for Immunology (LJI) have found that four COVID-19 vaccines (Pfizer-BioNTech, Moderna, J&J/Janssen, and Novavax) prompt the body to make effective, long-lasting T cells against SARS-CoV-2. Biology cells current fight Omicron teach Vaccines
Bio Pharma Dive
MAY 10, 2021
The emergency clearance greatly expands the pool of people who can be vaccinated in the U.S. just as some states are beginning to report waning demand
Bio Pharma Dive
DECEMBER 30, 2020
The first public vaccinations with AstraZeneca and Oxford’s shot will begin early in the New Year. But it’s still unclear how effective the vaccine is, or the best way to use it
Scienmag
NOVEMBER 2, 2021
Chemistry AND Physics engineering nextgen VaccinesMost researchers hope they will be the one to discover the next big breakthrough advance for society, like finding a cure for cancer or climate change.
Bio Pharma Dive
FEBRUARY 19, 2021
The drugmaker will use production lines at its plant in McPherson, Kansas to help fill vaccine vials, company CEO Albert Bourla said Friday
Bio Pharma Dive
FEBRUARY 27, 2021
The agency's emergency clearance makes J&J's vaccine the third available in the U.S., adding much-needed reinforcements at a critical time
Bio Pharma Dive
JULY 7, 2021
Having proved mRNA's might in COVID-19, the biotech company aims to develop similar vaccines for other respiratory illnesses caused by influenza, RSV and metapneumovirus
Bio Pharma Dive
JUNE 14, 2021
Highly anticipated results from a Phase 3 study testing the biotech company's shot showed it to be strongly protective and safe, a potential boon for the world's vaccination efforts
Scienmag
OCTOBER 29, 2021
A needle-free COVID-19 vaccination could be possible, with University of Queensland scientists successfully protecting mice from the virus by administering a US-developed vaccine candidate with a ‘patch’. Medicine & Health COVID19 Needlefree promise shows vaccine
My Local Study
OCTOBER 1, 2020
These differences also explain why vaccines are necessary for both the flu and COVID-19. Read more Flu Vaccine vs. COVID-19 Vaccine. The post Flu Vaccine vs. COVID-19 Vaccine appeared first on MyLocalStudy.com.
Bio Pharma Dive
FEBRUARY 4, 2021
The government-funded trial will evaluate the effects of mixing vaccines and varying timing between shots
Bio Pharma Dive
FEBRUARY 24, 2021
Agency scientists noted the shot's strong protection against severe COVID-19, even for the virus variant first detected in South Africa and known to weaken vaccine potency
Bio Pharma Dive
SEPTEMBER 8, 2021
The company has previously said it could make up to three billion vaccine doses in 2022, depending on how booster shots are authorized
Bio Pharma Dive
MAY 4, 2021
The sum is $11 billion higher than Pfizer had estimated in February and, if realized, would make the vaccine the highest grossing pharmaceutical product by revenue in a single year
Bio Pharma Dive
JANUARY 29, 2021
A deal to fill vials of Pfizer and BioNTech's vaccine could be the first of several Novartis signs to help others make COVID-19 treatments
Bio Pharma Dive
APRIL 1, 2021
One vaccine batch being manufactured for J&J by Emergent Biosolutions failed quality checks, reportedly ruining material sufficient for up to 15 million doses
Bio Pharma Dive
NOVEMBER 1, 2021
The FDA wants to better understand the risk of vaccine-associated myocarditis in 12- to 17-year-olds based on real-world use overseas, which will set back Moderna’s authorization plans in the U.S.
Scienmag
JANUARY 24, 2022
Despite low absolute risk, BNT162b2 COVID-19 vaccine associated with increased risk of carditis Markedly increased risk in adolescents after 2nd dose may warrant refined vaccination strategies Abstract: [link] URL goes live when the embargo lifts A case-control study found that despite low absolute risk, there is an increased relative risk of carditis associated with […]. Latest News BNT162b2 carditis COVID19 Increased risk vaccine
XTalks
OCTOBER 15, 2021
Moderna is facing criticism for refusing to share its COVID-19 vaccine formula amid global vaccine shortages and continuing COVID-19 vaccine inequities. However, on Tuesday, Moderna told The Associated Press that it has “no plans to share the recipe for its COVID-19 vaccine.”
Bio Pharma Dive
NOVEMBER 22, 2021
Four months after vaccination, no 12- to 15-year-olds in the companies' clinical trial developed COVID-19, compared to 30 who received a placebo
243 
Let's personalize your content